Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AbbVie, in collaboration with Genmab, is conducting a Phase 3 study titled A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The study aims to evaluate the safety and efficacy of epcoritamab plus lenalidomide (E-Len) versus rituximab plus gemcitabine and oxaliplatin (R-GemOx) in treating adult patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), a rare and aggressive cancer.
Intervention/Treatment: The study tests three interventions: Epcoritamab plus Lenalidomide (E-Len), Rituximab plus Gemcitabine and Oxaliplatin (R-GemOx), and Epcoritamab alone. Epcoritamab is an investigational drug administered subcutaneously, while Lenalidomide is taken orally, and the other drugs are given intravenously.
Study Design: This interventional study employs a randomized, parallel assignment model with no masking, focusing on treatment as its primary purpose. Participants are divided into three groups, each receiving different treatment regimens.
Study Timeline: The study began on July 11, 2024, with the latest update submitted on September 1, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
Market Implications: This study could significantly impact AbbVie’s stock performance and investor sentiment, particularly if the results show a favorable safety and efficacy profile for Epcoritamab. The competitive landscape in the treatment of DLBCL could shift, affecting both AbbVie and its competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.